Peptide therapy anxiety: what the science says about side effects

What did @filmedwithvictoria actually say?

She described a month-and-a-half peptide run using what sounds like Tesofensine ("Tessa"), Retatrutide ("Rata"), and GHK-Cu, during which she developed "debilitating anxiety attacks" with physical symptoms including numbness around the chest and diaphragm. She cut her Retatrutide dose way down, moved Tesofensine dosing to mornings, and eventually tried an antihistamine (Pepcid, an H2 blocker) alongside another antihistamine during an acute episode. She believes she may have mast cell activation syndrome (MCAS) or a histamine reaction driving the anxiety. GHK-Cu, she notes, never caused her problems. The core claim: these peptides triggered a histamine-mediated anxiety response in her body.

Does the science back this up?

Partly, yes. The histamine-anxiety connection is real and documented. Whether these specific compounds caused it is much harder to confirm, but the mechanism she stumbled onto is not made up.

Histamine acts as both an immune mediator and a neurotransmitter. H1 and H2 receptors are expressed in the central nervous system, and elevated histamine signaling has been linked to anxiety-like behavior in rodent models (Haas and Panula, 2003, Nature Reviews Neuroscience). Mast cell activation, whether triggered by foreign peptides or other compounds, can release histamine, tryptase, and prostaglandins that collectively produce autonomic symptoms, including racing heart, chest tightness, and what many patients describe as "anxiety."

Retatrutide is a GLP-1/GIP/glucagon triple agonist currently in Phase 2 trials. GLP-1 receptor agonists as a class have documented GI and autonomic side effects, and there is emerging discussion about their interaction with mast cell populations in the gut. Tesofensine is a triple monoamine reuptake inhibitor. It raises norepinephrine and dopamine, which will increase heart rate and can absolutely provoke anxiety at dose or in sensitive individuals. That is not a histamine story. That is just pharmacology.

What did they get wrong (or right)?

She got the antihistamine logic partially right but possibly for the wrong reasons for Tesofensine.

Using Pepcid (famotidine, an H2 blocker) alongside an H1 blocker to "cover both histamine pathways" is a legitimate clinical approach for suspected MCAS or histamine intolerance. Physicians do prescribe dual antihistamine regimens for this reason (Molderings et al., 2011, Journal of Hematology and Oncology). Credit where it is due: she connected real dots here.

However, attributing Tesofensine's anxiety effect purely to histamine is likely wrong. Tesofensine's norepinephrine reuptake inhibition is a more straightforward explanation for cardiovascular and anxiogenic symptoms. She even acknowledged "Tessa does increase your heart rate," which is the norepinephrine signal, not a histamine signal. These are different mechanisms requiring different management. Combining a stimulatory monoamine reuptake inhibitor with a GLP-1 class compound and a copper peptide is a stack with essentially no safety data in humans. The anxiety she experienced may be multi-factorial, and self-diagnosing it as purely MCAS risks missing the simpler explanation.

What should you actually know?

Several things here matter if you are considering any of these compounds or if you are already experiencing similar symptoms.

• Tesofensine is not an approved drug in the United States. Its cardiovascular and CNS side effects, including increased heart rate and anxiety, were documented in its clinical trials (Astrup et al., 2008, The Lancet). These are on-target effects of its mechanism, not necessarily an allergic response.
• Retatrutide is still in clinical trials. Its long-term safety profile, including any interaction with mast cell populations or histamine metabolism, is not established.
• MCAS is a real diagnosis, but it requires specific clinical criteria and workup (serum tryptase, urine histamine metabolites, symptom pattern). Self-diagnosing via TikTok and treating with over-the-counter antihistamines during an acute episode is not a diagnostic process.
• GHK-Cu has a relatively benign tolerability profile in the literature, which aligns with her report that it caused no anxiety. It does not have the same receptor-level stimulatory activity as the other two compounds.
• If you are experiencing chest numbness, diaphragm tightness, and debilitating anxiety on any peptide regimen, these are symptoms that warrant stopping the compound and contacting a licensed provider, not adjusting the dose based on AI chatbot research.

The bottom line

She did real detective work and landed on a plausible partial explanation. The histamine-anxiety link is scientifically grounded. But she may be conflating two different mechanisms: a possible histamine or mast cell reaction from Retatrutide, and a predictable noradrenergic effect from Tesofensine. Both can cause anxiety. Neither is well-studied in combination. The fix is not necessarily a lower dose or a different dosing time. It may be that this particular stack is not compatible with her physiology, and a clinician needs to be in that conversation, not just an AI assistant and a comment section.